Business Context and Reporting Period
This Form 8-K was filed by Silexion Therapeutics Corp on January 14, 2025. The filing addresses the retroactive adjustment of previously reported financial statements due to a 1-for-9 reverse share split approved by shareholders in November 2024 and effected on November 27, 2024. The adjustments apply to the unaudited financial statements for the quarter and nine months ended September 30, 2024, and the audited financial statements for the year ended December 31, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves solely to announce the availability of updated financial statements (Exhibits 99.1 and 99.2) that reflect the reduced share count and increased per-share price resulting from the reverse split. The original Q3 2024 results were previously reported on November 14, 2024.
Material Changes
- Reverse Share Split: A 1-for-9 reverse split of all issued and outstanding ordinary shares was effected on November 27, 2024.
- Financial Statement Adjustments: Share, per-share, option, and warrant information in the Q3 2024 and 2023 financial statements have been retroactively adjusted to reflect the split.
- Securities Registered: Ordinary Shares (SLXN) and Warrants (SLXNW) remain registered on The Nasdaq Stock Market LLC.
Guidance, Outlook, and Risks
The filing contains no new management commentary, forward-looking guidance, or specific risk factors beyond the procedural update regarding the share split. The company is identified as an emerging growth company. No unusual items or contingencies are described in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 for the updated unaudited financial statements for the periods ended September 30, 2024.
- Review Exhibit 99.2 for the updated audited financial statements for the year ended December 31, 2023.
- Verify the adjusted share count and per-share metrics (EPS, book value) against the pre-split figures.
- Confirm the exercise price of outstanding warrants ($103.50) and how the split impacts warrant terms.